LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

Interview with Bill Nankervis, Executive Vice President and Chief Operating Officer, Lallemand Group of Companies

18/05/2021
INTERVIEW

About Bill Nankervis

Bill holds a BSc in Mechanical Engineering and started his career in the chemical industry in South Africa and the UK (for ICI) before joining Anchor Yeast in South Africa. He relocated to the USA in 2007 to lead Lallemand’s Biofuels & Distilled Spirits business and, in 2011, he resettled in France (Toulouse) to assume leadership of the Specialties Division of the Group. He moved back to North America in 2014 in preparation for taking on the role of Executive VP & COO responsible for all business units and operations worldwide.

Interview with... Bill Nankervis, Executive Vice President and Chief Operating Officer, Lallemand Group of Companies

1) Lallemand is poised at an exciting time for industrial biotechnology – where do you see your greatest opportunities?
At Lallemand we are passionate about Yeast and Bacteria and about Biotechnology in general. We are fortunate that there are so many opportunities for further development in applications for yeast, bacteria and their derivatives. We have organised ourselves to be able to bring focus to different market areas and have more than 10 business units, each dedicated to researching, developing, producing and marketing products and solutions for customers and partners operating within those markets. We have big dreams about the future potential and I honestly believe each of these units is still in the development phase of what we can imagine delivering in future. Addressing the environment and climate crisis, improving plant health and productivity, food security and safety (with bio-preservation for example), animal and human health are all areas of great opportunity in addition to the more traditional food ingredient and beverage industries.

2) How has the company changed over the years as technologies advance?
We strive to be one of the leading players in all the areas that we chose to put effort and focus into. We are fortunate that this approach and the opportunities in the Biotechnology space have allowed us a long track record of growth as a Group.

Naturally this brings a lot of change over the years! Key to supporting this is ongoing reinvestment in our capabilities. Human resources are the most important in that respect and I am proud to be one of the leaders of a tremendously talented, committed and diverse team around the World. In addition, funding ongoing research and development, both internally and with key partners, as well as investment in production capacity and the supply chain that goes with that make us a significantly different organisation than just 10 years ago. Our core values, passion and vision however remain unchanged.

3) How is Lallemand planning to grow in Europe?
Our growth is driven by listening to our customers and partners and a willingness “to try”. Even if we do not have a ready solution, perhaps it is possible if we just try! That ethos and not fearing failure, using customer complaints as one vector for innovation (for example) is applied not only in Europe but across all our businesses around the World. I am convinced there remain many opportunities in Europe and we will continue to look for those that are right for us and invest accordingly.

We are encouraged by the European Commission’s Green Deal ambitions turning challenges into opportunities and ensuring a sustainable future economy. It is essential that there is an appropriate framework in Europe to encourage ongoing investment and innovation in Biotechnology if we hope to realise all the potential benefits Industrial Biotechnology has to offer our World.

4) How is your skills profile changing as the company grows?
Encouraging an entrepreneurial and innovative spirit and the ability to work both autonomously and in teams continues to be essential for Lallemand. Similarly developing young people who will ensure our future success. Skills profiles have changed as we have grown and will continue to evolve with the digital age and the need for specific new kinds of skills as technology develops.

Interview with Lallemand


Download
2021_05_G_O_Interview-with-LallemandDownload
Share
Communications Team
Communications Team

Related posts

14/07/2025

EuropaBio Annual Report 2025


Read more
11/07/2025

Industrial Decarbonisation Accelerator Act – EuropaBio Position


Read more
07/07/2025

EuropaBio Position on the Critical Medicines Act


Read more

Important links

  • Public Consultation Response to the European Commission’s 28th Regime proposal
  • EuropaBio Annual Report 2025

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.